Magenta Therapeutics prioritizes MGTA-117, cuts workforce 14%, extends cash runway into Q2 2024

Dianthus Therapeutics, Inc. /DE/

MGTA-117 Phase 1/2 trial shows encouraging early data: well-tolerated with no significant adverse events, early pharmacodynamic signals.
Company reduces workforce by 14% and extends cash runway into Q2 2024 through spending prioritization.
Magenta to disclose summary of clinical observations from initial MGTA-117 patients in Q1 2022 earnings release in early May.
De-prioritizing other portfolio investments, pausing MGTA-145 dosing optimization trial in healthy subjects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.